Seeking Alpha

More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five...

More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five fold from Q1; there were ~125K prescriptions filled during the period. The company, along with Forest Labs, is exploring "additional development opportunities to strengthen the clinical profile of Linzess." The two companies plan to report data from a Phase IIIb trial evaluating the drug on CIC patients' abdominal symptoms in Q3 and expect "to initiate U.S. clinical trials" for other indications in Q1 2014. IRWD reaffirms FY13 total sales and marketing expenses of $250-300M for the drug. Shares +10.65% premarket. (PR)
Comments (1)
  • Scrying Biotech
    , contributor
    Comments (1988) | Send Message
     
    Synergy shares should jump this week as well.
    23 Jul 2013, 08:32 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs